These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

3982 related items for PubMed ID: 6342772

  • 1. 4'-epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data.
    Ganzina F.
    Cancer Treat Rev; 1983 Mar; 10(1):1-22. PubMed ID: 6342772
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A phase II study of 4'-epi-doxorubicin plus cis-platinum in advanced solid tumors.
    Martoni A, Tomasi L, Farabegoli G, Giovannini M, Monetti N, Ganzina F, Pannuti F.
    Eur J Cancer Clin Oncol; 1984 Jan; 20(1):11-7. PubMed ID: 6581974
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Clinical evaluation of 4'-epi-doxorubicin in advanced solid tumors.
    Robustelli Della Cuna G, Pavesi L, Preti P, Ganzina F.
    Invest New Drugs; 1983 Jan; 1(4):349-53. PubMed ID: 6590532
    [Abstract] [Full Text] [Related]

  • 9. Phase-II clinical trial of 4'-epi-doxorubicin in metastatic solid tumors.
    Kolarić K, Potrebica V, Cervek J.
    J Cancer Res Clin Oncol; 1983 Jan; 106(2):148-52. PubMed ID: 6579052
    [Abstract] [Full Text] [Related]

  • 10. Epirubicin. Clinical pharmacology and dose-effect relationship.
    Robert J.
    Drugs; 1993 Jan; 45 Suppl 2():20-30. PubMed ID: 7693418
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Controlled phase III clinical study of 4-epi-doxorubicin + 5-fluorouracil versus 5-fluorouracil alone in metastatic gastric and rectosigmoid cancer.
    Kolarić K, Potrebica V, Stanovnik M.
    Oncology; 1986 Jan; 43(2):73-7. PubMed ID: 3513075
    [Abstract] [Full Text] [Related]

  • 13. [Epirubicin (4'-epi-adriamycin].
    Tsukagoshi S.
    Gan To Kagaku Ryoho; 1990 Jan; 17(1):151-9. PubMed ID: 2404456
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics of 4'-deoxy-4'-iodo-doxorubicin in plasma and tissues of tumor-bearing mice compared with doxorubicin.
    Formelli F, Carsana R, Pollini C.
    Cancer Res; 1987 Oct 15; 47(20):5401-6. PubMed ID: 3652044
    [Abstract] [Full Text] [Related]

  • 16. Comparative pharmacokinetics and metabolism of doxorubicin and 4-demethoxy-4'-O-methyldoxorubicin in tumor-bearing mice.
    Formelli F, Carsana R, Pollini C.
    Cancer Chemother Pharmacol; 1986 Oct 15; 16(1):15-21. PubMed ID: 3753554
    [Abstract] [Full Text] [Related]

  • 17. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L, Bramwell V, Moran LA.
    Cancer Prev Control; 1999 Apr 15; 3(2):145-59. PubMed ID: 10474762
    [Abstract] [Full Text] [Related]

  • 18. Phase II clinical evaluation of 4'-epi-doxorubicin.
    Hurteloup P, Cappelaere P, Armand JP, Mathé G.
    Cancer Treat Rep; 1983 Apr 15; 67(4):337-41. PubMed ID: 6573956
    [Abstract] [Full Text] [Related]

  • 19. Clinical toxicity of 4'-epi-doxorubicin (epirubicin).
    Ganzina F, Di Pietro N, Magni O.
    Tumori; 1985 Jun 30; 71(3):233-40. PubMed ID: 3861022
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 200.